CareDx Inc (CDNA)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $4.09B
Last updated: Nov 17, 2026 at 11:04 AM ET
CareDx Inc (CDNA) Financials: Revenue, Profit and Cash Flow
CareDx reported revenue of $379.81M for the fiscal year ended Dec 31, 2025, up 13.8% from the year before. That year, net income was -$21.35M with a net margin of -5.6%, operating cash flow was $42.03M and free cash flow was $36.12M. The quarter ended Jun 30, 2026 had revenue of $263.90M and net income of $110.64M.
Revenue and Margins
The operating margin was -8.1% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $40.63M, a compound annual rate of 28.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $379.81M | +13.8% | 67.6% | -8.1% | -5.6% |
| Dec 2024 | $333.79M | +19.1% | 67.1% | 12.2% | 15.7% |
| Dec 2023 | $280.32M | -12.9% | 63.6% | -72.5% | -67.9% |
| Dec 2022 | $321.79M | +8.6% | 65.1% | -24.0% | -23.8% |
| Dec 2021 | $296.40M | +54.2% | 67.1% | -10.0% | -10.3% |
| Dec 2020 | $192.19M | +51.3% | 67.2% | -11.7% | -9.7% |
| Dec 2019 | $127.07M | +66.0% | 64.2% | -19.3% | -17.3% |
| Dec 2018 | $76.57M | +58.4% | 56.9% | -20.3% | -61.1% |
| Dec 2017 | $48.32M | +18.9% | 55.8% | -42.0% | -115.0% |
| Dec 2016 | $40.63M | N/A | 48.0% | -91.9% | -97.8% |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Jun 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $379.81M | $333.79M | $280.32M | $321.79M | $296.40M | $192.19M | $127.07M | $76.57M | $48.32M | $40.63M |
| Cost of revenue | $123.24M | $109.70M | $102.07M | $112.21M | $97.39M | $63.12M | $45.45M | $32.99M | $21.37M | $21.12M |
| Gross profit | $256.57M | $224.09M | $178.26M | $209.58M | $199.01M | $129.08M | $81.61M | $43.58M | $26.95M | $19.51M |
| Research and development | $71.43M | $72.51M | $82.42M | $90.39M | $76.53M | $48.94M | $30.71M | $14.51M | $12.39M | $12.38M |
| Operating income | -$30.78M | $40.77M | -$203.36M | -$77.23M | -$29.73M | -$22.53M | -$24.53M | -$15.58M | -$20.29M | -$37.33M |
| Net income | -$21.35M | $52.55M | -$190.28M | -$76.61M | -$30.66M | -$18.71M | -$21.97M | -$46.78M | -$55.56M | -$39.76M |
| EBITDA | -$8.57M | $61.47M | -$187.11M | -$63.60M | -$19.23M | -$10.48M | -$17.79M | N/A | N/A | -$32.55M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $263.90M | $117.70M | $108.39M | $100.06M | $86.68M | $84.69M | $86.58M | $82.88M | $92.27M | $72.05M | $65.57M | $67.19M |
| Gross profit | $228.93M | $84.07M | $72.87M | $69.40M | $58.02M | $56.27M | $58.39M | $55.31M | $64.28M | $46.12M | $39.89M | $42.66M |
| Operating income | $113.22M | $1.20M | -$6.04M | -$246.00K | -$11.12M | -$13.37M | $84.38M | -$13.72M | -$7.33M | -$22.57M | -$122.63M | -$28.78M |
| Net income | $110.64M | $2.81M | -$4.11M | $1.68M | -$8.57M | -$10.35M | $87.70M | -$10.64M | -$4.62M | -$19.89M | -$118.10M | -$23.48M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $6.51M by $58.91M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $413.23M | $491.05M | $466.83M | $542.99M | $566.62M | $368.51M | $151.74M | $130.70M | $83.56M | $76.73M |
| Current assets | $257.13M | $351.83M | $313.71M | $387.85M | $433.36M | $273.10M | $71.92M | $81.11M | $26.77M | $26.67M |
| Cash and equivalents | $65.43M | $114.69M | $82.20M | $89.92M | $348.49M | $134.67M | $38.22M | $64.62M | $16.89M | $17.26M |
| Total liabilities | $110.13M | $112.62M | $205.50M | $112.08M | $100.75M | $90.83M | $52.74M | $34.77M | $89.52M | $56.97M |
| Short-term debt | $6.51M | $6.10M | $5.94M | $5.59M | $3.96M | $2.03M | $3.02M | $172.00K | $15.72M | $22.85M |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $18.34M | $1.10M |
| Shareholder equity | $303.10M | $378.43M | $261.33M | $430.91M | $465.88M | $277.68M | $99.00M | $95.93M | -$6.13M | $19.48M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $532.99M | $411.06M | $413.23M | $432.31M | $444.26M | $489.64M | $491.05M | $476.99M | $466.78M | $452.41M | $466.83M | $501.18M |
| Total liabilities | $107.39M | $97.53M | $110.13M | $121.17M | $116.89M | $110.29M | $112.62M | $203.74M | $202.11M | $196.18M | $205.50M | $107.05M |
| Cash and equivalents | $373.64M | $77.92M | $65.43M | $91.44M | $68.21M | $88.75M | $114.69M | $95.40M | $95.78M | $93.30M | $82.20M | $75.98M |
| Shareholder equity | $425.60M | $313.54M | $303.10M | $311.14M | $327.37M | $379.35M | $378.43M | $273.25M | $264.67M | $256.23M | $261.33M | $394.13M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 85.9% of operating cash flow. Share repurchases came to 243.0% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $42.03M | $38.05M | -$18.39M | -$25.24M | -$19.29M | $33.43M | -$2.77M | -$4.01M | -$14.31M | -$16.52M |
| Capital expenditures | $5.91M | $6.48M | $8.34M | $21.23M | $13.56M | $7.11M | $2.20M | $2.04M | $186.00K | $549.00K |
| Free cash flow | $36.12M | $31.56M | -$26.73M | -$46.47M | -$32.85M | $26.32M | -$4.97M | -$6.04M | -$14.49M | -$17.07M |
| Dividends paid | N/A | N/A | N/A | N/A | $2.14M | $1.37M | $4.42M | $26.76M | $0 | $0 |
| Share repurchases | $87.77M | $522.00K | $27.54M | $642.00K | $0 | $0 | N/A | N/A | N/A | N/A |
| Investing cash flow | $2.16M | -$483.00K | $40.45M | -$228.50M | $47.71M | -$100.39M | -$22.58M | -$7.93M | -$6.11M | -$21.12M |
| Financing cash flow | -$93.39M | -$5.61M | -$29.61M | -$4.54M | $185.64M | $163.15M | -$132.00K | $50.27M | $29.38M | $24.93M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $30.60M | $4.33M | $21.36M | $37.36M | $9.89M | -$26.58M | $21.89M | $12.52M | $18.95M | -$15.31M | -$8.38M | -$10.18M |
| Capital expenditures | $1.86M | $3.82M | $1.97M | $1.30M | $1.01M | $1.63M | $1.52M | $1.69M | $1.79M | $1.49M | $1.59M | $1.62M |
| Free cash flow | $28.75M | $514.00K | $19.39M | $36.05M | $8.89M | -$28.21M | $20.37M | $10.84M | $17.16M | -$16.80M | -$9.97M | -$11.80M |
Frequently Asked Questions About CDNA
What is CareDx's annual revenue?
CareDx reported revenue of $379.81M for the fiscal year ended Dec 31, 2025.
How fast is CareDx's revenue growing?
Revenue was up 13.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 5.7%.
Is CareDx profitable?
No. CareDx reported net income of -$21.35M for the fiscal year ended Dec 31, 2025, with a net margin of -5.6%.
How much free cash flow does CDNA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $42.03M minus capital expenditures of $5.91M produced free cash flow of $36.12M.
How much debt does CareDx have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $6.51M and cash and equivalents of $65.43M.
CDNA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts